Effects of anticoagulants on cancer: heparins.
Pineo
Graham F
GF
University of Calgary, South Tower Foothills Hospital, Unit 1633, 1632 - 14th AVE NW, Calgary, Alberta, T2N 1M7, Canada. graham.pineo@calgaryhealthregion.ca
Hull
Russell D
RD
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000502:physiology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005966:Glucuronidase / Q000502:physiology; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D019087:Selectins / Q000502:physiology; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000209:etiology; D013925:Thromboplastin / Q000502:physiology; D000099175:Heparanase
D000925:Anticoagulants; D000970:Antineoplastic Agents; D001779:Blood Coagulation Factors; D005966:Glucuronidase; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D019087:Selectins; D013917:Thrombin; D013925:Thromboplastin; D000099175:Heparanase